Literature DB >> 26843921

Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies.

Brendan Frett1, Nick McConnell1, Yuanxiang Wang1, Zhigang Xu2, Andrew Ambrose1, Hong-Yu Li3.   

Abstract

Trk receptors play a key role in the development and maintenance of neuronal networks. Recent evidence suggests that the Trk family, specifically TrkA, is an important driver for tumour growth, inflammatory and neuropathic pain, and chemoresistance. Through a computational screen, a novel Trk active pharmacophore was identified and a series of pyrazine-based inhibitors were developed, which potently inhibited TrkA. Inhibitors displayed the highest activity on TrkA when screened against a small, tyrosine kinase panel and also exhibited a non-linear SAR. Predicted binding modes of the inhibitors were examined, which identified exploitable regions for future development of more advanced inhibitors.

Entities:  

Year:  2014        PMID: 26843921      PMCID: PMC4734651          DOI: 10.1039/C4MD00251B

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  28 in total

1.  siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway.

Authors:  Dapeng Liu; Yong Zhang; Chengxue Dang; Qingyong Ma; Woo Lee; Wuke Chen
Journal:  Oncol Rep       Date:  2007-09       Impact factor: 3.906

Review 2.  Molecular basis of congenital insensitivity to pain with anhidrosis (CIPA): mutations and polymorphisms in TRKA (NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor.

Authors:  Y Indo
Journal:  Hum Mutat       Date:  2001-12       Impact factor: 4.878

3.  Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.

Authors:  Pam Albaugh; Yi Fan; Yuan Mi; Fangxian Sun; Francisco Adrian; Nanxin Li; Yong Jia; Yelena Sarkisova; Andreas Kreusch; Tami Hood; Min Lu; Guoxun Liu; Shenlin Huang; Zuosheng Liu; Jon Loren; Tove Tuntland; Donald S Karanewsky; H Martin Seidel; Valentina Molteni
Journal:  ACS Med Chem Lett       Date:  2012-01-01       Impact factor: 4.345

4.  Structure and chemical inhibition of the RET tyrosine kinase domain.

Authors:  Phillip P Knowles; Judith Murray-Rust; Svend Kjaer; Rizaldy P Scott; Sarah Hanrahan; Massimo Santoro; Carlos F Ibáñez; Neil Q McDonald
Journal:  J Biol Chem       Date:  2006-08-23       Impact factor: 5.157

5.  TrkA kinase inhibitors from a library of modified and isosteric Staurosporine aglycone.

Authors:  Rabindranath Tripathy; Thelma S Angeles; Shi X Yang; John P Mallamo
Journal:  Bioorg Med Chem Lett       Date:  2008-05-06       Impact factor: 2.823

6.  Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene.

Authors:  R J Smeyne; R Klein; A Schnapp; L K Long; S Bryant; A Lewin; S A Lira; M Barbacid
Journal:  Nature       Date:  1994-03-17       Impact factor: 49.962

7.  TrkA overexpression enhances growth and metastasis of breast cancer cells.

Authors:  C Lagadec; S Meignan; E Adriaenssens; B Foveau; E Vanhecke; R Romon; R-A Toillon; B Oxombre; H Hondermarck; X Le Bourhis
Journal:  Oncogene       Date:  2009-03-30       Impact factor: 9.867

8.  Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.

Authors:  Ben Davidson; Reuven Reich; Philip Lazarovici; Jahn M Nesland; Martina Skrede; Björn Risberg; Claes G Tropé; Vivi Ann Flørenes
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

9.  Identification of a Novel Series of Potent TrkA Receptor Tyrosine Kinase Inhibitors.

Authors:  Stéphane L Raeppel; Frédéric Gaudette; Hannah Nguyen; Normand Beaulieu; James Wang; Christiane Maroun; Jeffrey M Besterman; Arkadii Vaisburg
Journal:  Int J Med Chem       Date:  2012-05-02

10.  Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Authors:  A Vaishnavi; M Capelletti; P A Jänne; R C Doebele; A T Le; S Kako; M Butaney; D Ercan; S Mahale; K D Davies; D L Aisner; A B Pilling; E M Berge; J Kim; H Sasaki; S Park; G Kryukov; L A Garraway; Peter S Hammerman; J Haas; S W Andrews; D Lipson; P J Stephens; V A Miller; M Varella-Garcia
Journal:  Nat Med       Date:  2013-10-27       Impact factor: 53.440

View more
  3 in total

1.  Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-a]pyridine derivatives.

Authors:  Brendan Frett; Nicholas McConnell; Anupreet Kharbanda; Gunaganti Naresh; Benjamin Rounseville; Christina Warner; John Chang; Natalie Debolske; Hong-Yu Li
Journal:  Tetrahedron       Date:  2018-07-17       Impact factor: 2.457

2.  Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.

Authors:  Lingtian Zhang; Naga Rajiv Lakkaniga; Jaideep B Bharate; Nicholas Mcconnell; Xiuqi Wang; Anupreet Kharbanda; Yuet-Kin Leung; Brendan Frett; Neil P Shah; Hong-Yu Li
Journal:  Eur J Med Chem       Date:  2021-08-17       Impact factor: 7.088

3.  Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT.

Authors:  Jaideep B Bharate; Nicholas McConnell; Gunaganti Naresh; Lingtian Zhang; Naga Rajiv Lakkaniga; Lucky Ding; Neil P Shah; Brendan Frett; Hong-Yu Li
Journal:  Sci Rep       Date:  2018-02-27       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.